Rethinking the appraisal and approval of drugs for type 2 diabetes

Naci, Huseyin, Lehman, Richard, Wouters, Olivier J. ORCID: 0000-0002-2514-476X, Goldacre, Ben and Yudkin, John S (2015) Rethinking the appraisal and approval of drugs for type 2 diabetes. BMJ, 351 (h5260). ISSN 1756-1833

Preview

PDF - Accepted Version Download (552kB) | Preview

• Author

Abstract

The process for approving new drugs for type 2 diabetes illustrates the significant shortcomings of the regulatory standards for licensing, reimbursing, and adopting new drugs. Regulatory reform is needed to improve the real-world therapeutic value of anti-diabetic drugs.

Item Type:	Article
Official URL:	http://www.bmj.com/
Additional Information:	© 2015 BMJ Publishing Group Ltd
Divisions:	LSE Health
Subjects:	R Medicine > RA Public aspects of medicine
Date Deposited:	22 Oct 2015 14:03
Last Modified:	24 Apr 2024 21:12
URI:	http://eprints.lse.ac.uk/id/eprint/64115

Actions (login required)

View Item